February 22nd, 2013
SYNTAX After 5 Years: Any Change in Results (or Your Practice)?
Richard A. Lange, MD, MBA and L. David Hillis, MD
The 5 year results of the SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial are now published. SYNTAX assessed the optimal revascularization strategy for patients with left main and/or 3-vessel disease by randomly assigning such patients to CABG or PCI (with a first-generation paclitaxel-eluting stent) and then determining the rate of […]
September 13th, 2010
SYNTAX at 3 years: CABG Still Winning, but PCI Acceptable in Low-Risk Patients
Larry Husten, PHD
Three-year outcomes from the SYNTAX trial continue to show the overall superiority of CABG over PCI in patients with complex disease, but they leave room for the use of PCI in patients with low-risk disease. The results of the trial were presented by A. Pieter Kappetein at the European Association of Cardio-Thoracic Surgery annual meeting in Geneva, Switzerland. […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?